Showing 34,980 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Injectable & long-acting HIV treatment

Interim BHIVA guidance on long-acting cabotegravir/rilpivirine (LA-CAB/RPV) for antiretroviral therapy

Editor's pick
BHIVA
7 February 2022
Economic & social inequality

HIV diagnoses among Black adults highest in US communities with more social vulnerabilities

Editor's pick
Healio
7 February 2022
Coronavirus

South African Scientists Will Study Link Between COVID Variants and Untreated HIV

Editor's pick
Medscape (requires free registration)
7 February 2022
Global health targets

How HIV elimination is within Australia's reach

Editor's pick
BBC News
7 February 2022
Epidemiology

Men who pay for sex: a missing at-risk population?

Editor's pick
Avert
7 February 2022
The search for an HIV prevention vaccine

Analysis: Moderna's HIV Vaccine Trial Will Advance Many Companies' mRNA Plans

Editor's pick
The Washington Post
7 February 2022
Pharmaceutical industry

Deborah Waterhouse: ‘The HIV stigma remains, and this is a battle we’ve got to fight’

Editor's pick
The Guardian
7 February 2022
How HIV works

Why You Don’t Need to Worry About the Newly Identified “Highly Virulent” Strain of HIV

Editor's pick
POZ
7 February 2022

aidsmap news: People with unsuppressed viral load have weaker antibody responses to COVID-19 vaccine, 7 February 2022

February 2022
Types of HIV tests

How accurate are fourth-generation combination tests for HIV diagnosis? A research briefing

About HIV
February 2022
How HIV works

A 'highly virulent' HIV strain is 'no cause for alarm,' scientists say

Editor's pick
NBC News
4 February 2022
Improving HIV care

Does your patient living with HIV need advice, empathy, or something different?

News
4 February 2022
Coronavirus

People with unsuppressed viral load have weaker antibody responses to COVID-19 vaccine

News
3 February 2022

Gay men and fatherhood – HIV update, 2 February 2022

February 2022
PrEP policies & guidelines

When you're charged a PrEP copay you shouldn't owe

Editor's pick
Axios
2 February 2022
Pharmaceutical industry

GSK to get $1.25 bln to settle HIV drug patent row with Gilead

Editor's pick
Reuters
2 February 2022
Experiences of stigma

HIV Stigma Persists Globally, According to Harris Poll

Editor's pick
Medscape (requires free registration)
2 February 2022
Global health initiatives

Governments are 'trying to muzzle WHO,' says HIV activist

Editor's pick
Devex
2 February 2022
Harm reduction

It’s Time for Maine to Free Us From One-to-One Syringe Distribution

Editor's pick
Filter
2 February 2022
Cancer

French researchers investigate second cancers in people with HIV who survived a first cancer

Editor's pick
CATIE
2 February 2022
Treatment outcomes & life expectancy

Improvements in survival for people with HIV continue to be achieved

Editor's pick
CATIE
2 February 2022
People who inject drugs

Tele-harm reduction: a new approach in the US shows promise for people with HIV who inject drugs

News
2 February 2022
Injectable & long-acting HIV treatment

ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

Editor's pick
ViiV press release
1 February 2022
HIV treatment

Cabotegravir and rilpivirine injections Factsheet

About HIV
February 2022